{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:15:42Z","timestamp":1755036942398,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03505-4","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T21:15:45Z","timestamp":1677014145000},"page":"1865-1873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-5830","authenticated-orcid":false,"given":"Massimo","family":"Morosetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ljiljana","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Zappal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Agafonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Pryshlyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"3505_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2362.2007.01840.x","volume":"37","author":"B Kestenbaum","year":"2007","unstructured":"Kestenbaum B, Belozeroff V (2007) Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest 37:607\u2013622. https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01840.x","journal-title":"Eur J Clin Invest"},{"key":"3505_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.0894-0959.2004.17308.x","volume":"17","author":"WG Goodman","year":"2004","unstructured":"Goodman WG (2004) The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 17:209\u2013216. https:\/\/doi.org\/10.1111\/j.0894-0959.2004.17308.x","journal-title":"Semin Dial"},{"key":"3505_CR3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.61.s80.26.x","author":"M Rodriguez","year":"2002","unstructured":"Rodriguez M, Canalejo A, Garfia B et al (2002) Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int Suppl. https:\/\/doi.org\/10.1046\/j.1523-1755.61.s80.26.x","journal-title":"Kidney Int Suppl"},{"issue":"S49","key":"3505_CR4","first-page":"S30","volume":"26","author":"M Cozzolino","year":"2009","unstructured":"Cozzolino M, Olivi L, Voli E et al (2009) PREVENZIONE E TRATTAMENTO DELL\u2019IPERPARATIROIDISMO SECONDARIO NEL PAZIENTE CON MALATTIA RENALE CRONICA ALLO STADIO NON IN DIALISI. G Ital Nefrol 26(S49):S30\u2013S35","journal-title":"G Ital Nefrol"},{"key":"3505_CR5","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. https:\/\/doi.org\/10.1038\/ki.2009.188","DOI":"10.1038\/ki.2009.188"},{"key":"3505_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"K Disease","year":"2011","unstructured":"Disease K (2011) Improving global outcomes (KDIGO) CKD-MBD update work group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001","journal-title":"Kidney Int Suppl"},{"key":"3505_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int 92:26\u201336. https:\/\/doi.org\/10.1016\/j.kint.2017.04.006","journal-title":"Kidney Int"},{"key":"3505_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","volume":"70","author":"T Isakova","year":"2017","unstructured":"Isakova T, Nickolas TL, Denburg M et al (2017) KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 70:737\u2013751. https:\/\/doi.org\/10.1053\/j.ajkd.2017.07.019","journal-title":"Am J Kidney Dis"},{"key":"3505_CR9","volume-title":"Feingold KR","author":"TB Dr\u00fceke","year":"2000","unstructured":"Dr\u00fceke TB (2000) Hyperparathyroidism in Chronic Kidney Disease. In: Anawalt B, Boyce A et al (eds) Feingold KR. Endotext. MDText.com Inc, South Dartmouth (MA)"},{"key":"3505_CR10","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22636.1","author":"ME Rodr\u00edguez-Ortiz","year":"2020","unstructured":"Rodr\u00edguez-Ortiz ME, Rodr\u00edguez M (2020) Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. FRes. https:\/\/doi.org\/10.12688\/f1000research.22636.1","journal-title":"FRes"},{"key":"3505_CR11","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.2147\/DDDT.S134103","volume":"12","author":"C Friedl","year":"2018","unstructured":"Friedl C, Zitt E (2018) Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. Drug Des Devel Ther 12:1589\u20131598. https:\/\/doi.org\/10.2147\/DDDT.S134103","journal-title":"Drug Des Devel Ther"},{"key":"3505_CR12","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1681\/ASN.2006080936","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser D, Kollerits B, Neyer U et al (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) Study. J Am Soc Nephrol 18:2600\u20132608. https:\/\/doi.org\/10.1681\/ASN.2006080936","journal-title":"J Am Soc Nephrol"},{"key":"3505_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2215\/CJN.12941213","volume":"10","author":"F Tentori","year":"2015","unstructured":"Tentori F, Wang M, Bieber BA et al (2015) Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol 10:98\u2013109. https:\/\/doi.org\/10.2215\/CJN.12941213","journal-title":"Clin J Am Soc Nephrol"},{"key":"3505_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, Baruch A, Dong J et al (2013) Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 346:229\u2013240. https:\/\/doi.org\/10.1124\/jpet.113.204834","journal-title":"J Pharmacol Exp Ther"},{"key":"3505_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1471-2369-15-81","volume":"15","author":"S Walter","year":"2014","unstructured":"Walter S, Baruch A, Alexander ST et al (2014) Comparison of AMG 416 and cinacalcet in rodent models of uremia. BMC Nephrol 15:81. https:\/\/doi.org\/10.1186\/1471-2369-15-81","journal-title":"BMC Nephrol"},{"key":"3505_CR16","unstructured":"PubChem Etelcalcetide. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/71511839. Accessed 12 June 2021"},{"key":"3505_CR17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1124\/mol.115.098392","volume":"88","author":"ST Alexander","year":"2015","unstructured":"Alexander ST, Hunter T, Walter S et al (2015) Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol 88:853\u2013865. https:\/\/doi.org\/10.1124\/mol.115.098392","journal-title":"Mol Pharmacol"},{"key":"3505_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/jcph.460","volume":"55","author":"P Chen","year":"2015","unstructured":"Chen P, Melhem M, Xiao J et al (2015) Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol 55:620\u2013628. https:\/\/doi.org\/10.1002\/jcph.460","journal-title":"J Clin Pharmacol"},{"key":"3505_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/ckj\/sfx125","volume":"11","author":"L Pereira","year":"2018","unstructured":"Pereira L, Meng C, Marques D, Fraz\u00e3o JM (2018) Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clin Kidney J 11:80\u201388. https:\/\/doi.org\/10.1093\/ckj\/sfx125","journal-title":"Clin Kidney J"},{"key":"3505_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2016.19456","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cunningham J et al (2017) Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 317:146\u2013155. https:\/\/doi.org\/10.1001\/jama.2016.19456","journal-title":"JAMA"},{"key":"3505_CR21","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/ndt\/gfz039","volume":"35","author":"DA Bushinsky","year":"2020","unstructured":"Bushinsky DA, Chertow GM, Cheng S et al (2020) One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transplant 35:1769\u20131778. https:\/\/doi.org\/10.1093\/ndt\/gfz039","journal-title":"Nephrol Dial Transplant"},{"key":"3505_CR22","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.ekir.2020.09.010","volume":"5","author":"Y Itano","year":"2020","unstructured":"Itano Y, Kato S, Tsuboi M et al (2020) A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET Trial). Kidney Int Rep 5:2168\u20132177. https:\/\/doi.org\/10.1016\/j.ekir.2020.09.010","journal-title":"Kidney Int Rep"},{"key":"3505_CR23","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/ndt\/gfw408","volume":"32","author":"M Fukagawa","year":"2017","unstructured":"Fukagawa M, Yokoyama K, Shigematsu T et al (2017) A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32:1723\u20131730. https:\/\/doi.org\/10.1093\/ndt\/gfw408","journal-title":"Nephrol Dial Transplant"},{"key":"3505_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8071066","author":"D Russo","year":"2019","unstructured":"Russo D, Tripepi R, Malberti F et al (2019) Etelcalcetide in patients on hemodialysis with severe secondary hyperparathyroidism multicenter study in \u201creal life.\u201d J Clin Med. https:\/\/doi.org\/10.3390\/jcm8071066","journal-title":"J Clin Med"},{"key":"3505_CR25","unstructured":"Anonymous (2018) Parsabiv. In: European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/parsabiv. Accessed 12 June 2021"},{"key":"3505_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s10157-017-1442-5","volume":"22","author":"T Shigematsu","year":"2018","unstructured":"Shigematsu T, Fukagawa M, Yokoyama K et al (2018) Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 22:426\u2013436. https:\/\/doi.org\/10.1007\/s10157-017-1442-5","journal-title":"Clin Exp Nephrol"},{"key":"3505_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17041238","author":"GB Piccoli","year":"2020","unstructured":"Piccoli GB, Trabace T, Chatrenet A et al (2020) New intravenous calcimimetic agents: new options, new problems. An example on how clinical economical and ethical considerations affect choice of treatment. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph17041238","journal-title":"Int J Environ Res Public Health"},{"key":"3505_CR28","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","volume":"20","author":"A Makady","year":"2017","unstructured":"Makady A, de Boer A, Hillege H et al (2017) What Is Real-World Data? A review of definitions based on literature and stakeholder interviews. Value Health 20:858\u2013865. https:\/\/doi.org\/10.1016\/j.jval.2017.03.008","journal-title":"Value Health"},{"key":"3505_CR29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.2083","volume":"109","author":"H-G Eichler","year":"2021","unstructured":"Eichler H-G, Pignatti F, Schwarzer-Daum B et al (2021) Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther 109:1212\u20131218. https:\/\/doi.org\/10.1002\/cpt.2083","journal-title":"Clin Pharmacol Ther"},{"key":"3505_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","volume":"10","author":"LP Garrison","year":"2007","unstructured":"Garrison LP, Neumann PJ, Erickson P et al (2007) Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health 10:326\u2013335. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00186.x","journal-title":"Value Health"},{"key":"3505_CR31","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208\u20132218. https:\/\/doi.org\/10.1097\/01.ASN.0000133041.27682.A2","journal-title":"J Am Soc Nephrol"},{"key":"3505_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamacardio.2017.0363","volume":"2","author":"J Chen","year":"2017","unstructured":"Chen J, Budoff MJ, Reilly MP et al (2017) Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol 2:635\u2013643. https:\/\/doi.org\/10.1001\/jamacardio.2017.0363","journal-title":"JAMA Cardiol"},{"key":"3505_CR33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2298\/vsp0812893p","volume":"65","author":"D Petrovi\u0107","year":"2008","unstructured":"Petrovi\u0107 D, Stojimirovi\u0107 B (2008) Cardiovascular morbidity and mortality in patients treated with hemodialysis\u2013epidemiological analysis. Vojnosanit Pregl 65:893\u2013900. https:\/\/doi.org\/10.2298\/vsp0812893p","journal-title":"Vojnosanit Pregl"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03505-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03505-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03505-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:38:38Z","timestamp":1687783118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03505-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["3505"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03505-4","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}